Stay updated with breaking news from Planned Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Third-Quarter 2022 Results: -- Net Sales of $925.4 Million -- -- GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia Presented at European Hematology Association Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study... | August 12, 2022
Second-Quarter 2022 Results:-- Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million ---- GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million ---- TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million ---- KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Milli...
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple